Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-29

There’s always calculated risks & sure if data is good on completion of the trial - it will be much higher - but still “completion of the trial” & 8 months assuming last pt is dosed by end of quarter - it’s not “drug in market” it’s not even data from completion of the trial ….

Itsgas needs a bit of initiative geez - so you love AEF when they buy at big discounts - but you hate them when they sell higher for a profit - and then you love them again when they buy back at big discounts ?

I don’t need to listen to anybody - but you can keep taking note